IPO Market Unlocking for 'Omics-related Companies, but It's 'Anything but Robust' | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – For most of 2010, the IPO market froze out the life science tools and 'omics market, but by the end of the summer, there were signs that the public markets may be slowly welcoming firms operating in the space, as a handful of public offerings ended a cold snap.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.